Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes

Endocrinology & Metabolism Clinics of North America · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles